Biotech Startups

Another Food develops cell-cultured coffee, producing coffee from cultivated coffee plant cells in a lab rather than growing beans on farms. It positions its technology as using less water, fewer greenhouse gas emissions and no land to create a nature-identical coffee product.

2 investors

Ansun develops novel therapeutic treatments targeting viral diseases, particularly respiratory infections, through its proprietary sialic acid biology platform. The company focuses on unmet medical needs in immunocompromised and underserved patient populations.

2 investors

Antalgenics develops drugs and neurocosmetical products targeting dermatological and inflammatory conditions such as psoriatic pruritus, arthritic pain, and sensitive skin. The company focuses on pharmaceutical and cosmetic ingredient innovation for healthcare and personal care markets.

2 investors

Antengene is a biopharmaceutical company that develops therapies for cancer, with a pipeline focused on hematologic malignancies and solid tumors including Claudin 18.2, CD73, PD-L1/4-1BB bispecific, and CD24-targeting candidates. It is listed on the Hong Kong Stock Exchange and works with global partners on oncology drug development.

2 investors

Developing products for diseases associated with inflammation. (NASDAQ: ANTH)

2 investors

Antler Bio develops RNA data analysis technology for dairy farmers, revealing gene expression patterns in farm animals to improve health, productivity and decision-making. The company's platform, EpiHerd, identifies the biological factors affecting animal performance including milk yield, fertility and feed efficiency.

2 investors

Anuncia Medical develops medical technology focused on cerebrospinal fluid (CSF) science and clinical strategy to advance hydrocephalus treatment. The company combines decades of medtech expertise to serve the hydrocephalus care market.

2 investors

Anvil Diagnostics develops molecular diagnostic tests for invasive infections using proprietary SKIP-Seq technology that combines PCR speed with sequencing breadth. The company serves clinical laboratories and healthcare providers seeking rapid, direct-from-blood pathogen identification and antimicrobial guidance.

2 investors

AorticLab develops medical devices and solutions for cardiovascular applications. The company focuses on innovative treatment platforms and educational programs for patients and healthcare professionals.

2 investors

APASOMICS develops Apasomes, a drug delivery system using hydroxyapatite nanospheres designed to deliver bone-targeting medications like bisphosphonates more effectively while reducing side effects, for patients with osteoporosis and other bone diseases.

2 investors

Apeiron Investment Group is a discretionary, multi-strategy investment firm managing approximately $7 billion, making direct investments in private and listed companies as well as anchor LP investments and GP stakes in emerging asset managers. It invests across sectors with a focus on biotech, fintech and crypto, deep tech, hospitality and sports, real estate, and natural resources, with a primary focus on the US.

2 investors

Apexian Pharma is a biopharmaceutical company developing APX3330, an oral drug for treating Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis, as a single agent or in combination. It targets upstream modulation of inflammation for IBD patients who fail to achieve durable remission on current therapies.

2 investors

APIM Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics that disrupt cellular stress responses and address treatment resistance in cancer. Its lead candidate, ATX-101, has been evaluated in Phase Ib and Phase II clinical studies for ovarian cancer and soft tissue sarcoma.

2 investors

Apnimed develops investigational oral pharmaceutical therapies for obstructive sleep apnea (OSA), including its lead clinical candidate AD109, a neuromuscular approach intended to treat undertreated and untreated OSA patients. It is a clinical-stage pharmaceutical company focused on sleep apnea.

2 investors

Apostle develops cell-free DNA (cfDNA) extraction and purification kits for genomics and molecular biology laboratories. Its products are used to isolate DNA from plasma samples for downstream analysis, positioned as an alternative to established extraction kits.

2 investors

Appello Pharma is a biopharmaceutical company focused on drug discovery and development for neurological and metabolic diseases. The company leverages scientific expertise and infrastructure to advance novel therapeutics through preclinical and clinical development.

2 investors

FDA-cleared fully automated high-throughput multiplex molecular diagnostics system (TWSE:6598).

2 investors

Applyo-Jena manufactures molecular biology reagent mixtures and beads for PCR and isothermal amplification applications. The products are designed for research laboratories and diagnostic manufacturers, with formulations optimized for room-temperature stability and rapid assay setup.

2 investors

Apriori Bio applies AI/ML combined with biological insights to predict how viruses evolve and to design vaccines, assessing their expected performance before clinical trials. The company operates in the vaccinology and biotech space.

2 investors

APstem develops regenerative medicine therapies based on the activation of dormant pluripotent cells found in adult blood, with an initial focus on treating Type 1 Diabetes and other currently incurable diseases.

2 investors

aptaTargets develops aptamer-based therapeutics and diagnostics for cerebrovascular diseases, with a lead program (ApTOLL) targeting stroke treatment. The company applies aptamer technology platforms to clinical applications in neurology.

2 investors

The site presents ICON, a clinical research organization providing full-service drug development outsourcing, regulatory strategy, and clinical trial solutions for pharmaceutical and biotech sponsors. Its offerings include AI-enabled platforms for the clinical trial lifecycle, early-phase and bioanalytical services, cardiac safety monitoring, specialty laboratory services, and market access consulting.

2 investors

AptsciAptamer Science develops aptamer-based drug delivery and diagnostic platforms for precision medicine applications. The company specializes in cancer therapeutics using its proprietary ApDC (Aptamer-Drug Conjugate) technology, as well as early-stage lung cancer diagnostic kits and emerging programs in immunotherapy and metabolic disease.

2 investors

Through-the-endoscope vapor ablation platform for treating metabolic disease and type 2 diabetes via transoral duodenal ablation

2 investors